Hansen Medical CEO Discusses Q1 2011 Results - Earnings Call Transcript

Hansen Medical, Inc. (HNSN)

Q1 2011 Earnings Call

May 4, 2011 5:00 pm ET

Executives

Matt Clawson – IR, Allen & Caron Inc.

Bruce Barclay – President and CEO

Peter Osborne – Interim CFO

Analysts

Jeffrey Cohen – C.K.Cooper

Presentation

Operator

Compare to:
Previous Statements by HNSN
» Hansen Medical CEO Discusses Q4 2010 - Earnings Call Transcript
» Hansen Medical CEO Discusses Q3 2010 Results – Earnings Call Transcript
» Hansen Medical, Inc. Q2 2010 Earnings Call Transcript
» Hansen Medical, Inc. Q4 2009 Earnings Call Transcript

Good afternoon, ladies and gentlemen, thank you for standing by. Welcome to the Hansen Medical 2011 first quarter results conference call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be opened for question. (Operator instructions)

I would now like to turn the conference over to Mr. Matt Clawson, of Allen & Caron. Please go ahead sir.

Matt Clawson

Thank you, Jeremy. Good afternoon, everyone. Welcome to Hansen Medical’s 2011 first quarter results conference call. With us today are Hansen Medical President and CEO, Bruce Barclay; and the Company’s Interim Chief Financial Officer, Peter Osborne.

Before I turn the call over to management, please remember that our prepared remarks and responses to questions will contain forward-looking statements that are subject to a number of risks and uncertainties, the examples of such statements include statements about the expected timing of commercial availability of our vascular robot system, the level of clinical interest in our vascular robotic system, expectations regarding commercial success of our Lynx irrigated catheter and expectations regarding the final accounting treatment in the company’s first quarter transactions with Philips.

Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include, among others, that the development of new products and applications of technology are subject to design, engineering and manufacture challenges that could delays clinical studies.

1 2 3 Next › Last »